Charlotte-based Pelican Life Sciences (www.pelicanls.com), a company that facilitates life science research by providing products for discovery and detection, recently announced it has secured $100 million in private equity funding for acquisitions and development. The $100 million in equity capital commitments was raised through Grotech Capital Group and Ferrer Freeman & Company, LLC.

The funds will be used to acquire companies with proven track records of providing high-quality, differentiated products to support the pharmaceutical, biotech, and academic research market. Pelican is also expecting to make significant investments in the acquired entities to support product development, streamline manufacturing operations and expand sales and marketing capabilities.